Nebulized hypertonic saline 3% for 1 versus 3 days in hospitalized bronchiolitis: a blinded non-inferiority randomized controlled trial

Table 3 Tolerance study

	Total n = 116	HS1d n = 59	HS3d n = 57	p-value
Clinical worsening^a (n, %)	11 (9.5)	5 (8.4)	6 (10.5)	0.706
Length of stay > 6 days (n, %)	6 (5.2)	3 (5)	3 (5.2)	1.000
Treatment intolerance^b (n, %)	5 (4.3)	3 (5)	1 (1.7)	0.745

^aWang CSS > 9 at any time, necessity for a transfer to the PICU, need for ventilatory support, requirement for additional treatment such as inhaled bronchodilators
^bExcessive cough or desaturation during nebulization, or any clinically significant event related to the nebulization

ISSN: 1471-2431